Home / Stocks / RVTY

Revvity (RVTY, Life Sciences Tools & Services) Stock Valuation & Fair Value Significantly overvalued

Revvity (RVTY, Life Sciences Tools & Services) trades at a blended P/E of 28.7, about 48% above its historical normal valuation, with a forward growth estimate of 9.4% and a PEG of 3.05. Analysts' one-year estimates have been hit 64% of the time. Priced at its historical normal P/E of 19.4 on the same blended earnings, the 2026-10-02 close of $151.53 corresponds to about $102 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-05
Blended P/E
28.7
Normal P/E
19.4
PEG
3.05
Fwd growth
9.4%
Div yield
0.2%
RSI (14)
63.6
Neutral
Technical context
  • Price $152.16 at the 2026-10-08 close, 3.7% above the 20-day average ($146.67) and 15.9% above the 50-day ($131.28).
  • RSI (14) at 63.6.
  • 52-week range $82.21 to $157.36: the price is 3.3% below the high and 85.1% above the low.

The Street vs SeerForecast

Wall Street's mean price target for RVTY is $130.27 across 15 analysts, 14.4% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from weak on forward returns (2026-06-03) to significantly overvalued (2026-10-05).

Blended P/E and rating by weekBlended P/E moved from 19.7 to 28.7 between 2026-06-03 and 2026-10-02, against a normal P/E of 19.4, with 3 rating changes over 37 recorded weeks.2026-06-03: P/E 19.7, Weak on forward returns, recalculated for the week of 2026-06-032026-06-10: P/E 19.1, Weak on forward returns, recalculated for the week of 2026-06-102026-06-12: P/E 19.1, Weak on forward returns, recalculated for the week of 2026-06-142026-06-16: P/E 19.1, Weak on forward returns, recalculated for the week of 2026-06-162026-06-18: P/E 19.1, Weak on forward returns, recalculated for the week of 2026-06-212026-07-02: P/E 21.9, Weak on forward returns, recalculated for the week of 2026-07-022026-07-06: P/E 22.1, Weak on forward returns, recalculated for the week of 2026-07-062026-07-09: P/E 22.1, Weak on forward returns, recalculated for the week of 2026-07-092026-07-10: P/E 21.8, Weak on forward returns, recalculated for the week of 2026-07-122026-07-13: P/E 21.8, Weak on forward returns, recalculated for the week of 2026-07-132026-07-14: P/E 21.8, Weak on forward returns, recalculated for the week of 2026-07-142026-07-20: P/E 21.3, Weak on forward returns, recalculated for the week of 2026-07-202026-07-22: P/E 21.3, Weak on forward returns, recalculated for the week of 2026-07-222026-07-24: P/E 21.4, Weak on forward returns, recalculated for the week of 2026-07-252026-07-27: P/E 21.4, Weak on forward returns, recalculated for the week of 2026-07-272026-07-31: P/E 22.0, Weak on forward returns, recalculated for the week of 2026-07-312026-07-31: P/E 21.8, Weak on forward returns, recorded live 2026-08-032026-08-07: P/E 21.8, Weak on forward returns, recalculated for the week of 2026-08-072026-08-07: P/E 21.9, Weak on forward returns, recorded live 2026-08-102026-08-14: P/E 22.4, Weak on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 22.3, Weak on forward returns, recorded live 2026-08-172026-08-21: P/E 23.7, Trading above its usual valuation, recalculated for the week of 2026-08-212026-08-21: P/E 23.8, Trading above its usual valuation, recorded live 2026-08-242026-08-27: P/E 23.8, Trading above its usual valuation, recalculated for the week of 2026-08-272026-08-28: P/E 24.7, Poor on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 24.5, Poor on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 24.5, Poor on forward returns, recorded live 2026-08-312026-09-04: P/E 24.8, Poor on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 24.8, Poor on forward returns, recorded live 2026-09-072026-09-11: P/E 23.6, Trading above its usual valuation, recalculated for the week of 2026-09-122026-09-11: P/E 23.6, Trading above its usual valuation, recorded live 2026-09-142026-09-18: P/E 27.2, Significantly overvalued, recalculated for the week of 2026-09-192026-09-18: P/E 27.2, Significantly overvalued, recorded live 2026-09-212026-09-25: P/E 28.7, Significantly overvalued, recalculated for the week of 2026-09-262026-09-25: P/E 28.7, Significantly overvalued, recorded live 2026-09-282026-10-02: P/E 28.7, Significantly overvalued, recalculated for the week of 2026-10-032026-10-02: P/E 28.7, Significantly overvalued, recorded live 2026-10-0520.022.525.027.5Jun 3Jul 3Aug 2Sep 2Oct 2Normal P/E 19.4
Weak on forward returnsTrading above its usual valuationPoor on forward returnsSignificantly overvaluedLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 19.7+1%Weak on forward returns (recalculated)
2026-06-10P/E 19.1-1%Weak on forward returns (recalculated)
2026-08-28P/E 24.7+27%Poor on forward returns (recalculated)
2026-09-12P/E 23.6+22%Trading above its usual valuation (recalculated)
2026-09-19P/E 27.2+40%Significantly overvalued (recalculated)
2026-10-03P/E 28.7+48%Significantly overvalued (recalculated)
2026-10-05P/E 28.7+48%Significantly overvalued ← now
Show all 37 weeks
WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 19.7+1%Weak on forward returns (recalculated)
2026-06-10P/E 19.1-1%Weak on forward returns (recalculated)
2026-06-14P/E 19.1-1%Weak on forward returns (recalculated)
2026-06-16P/E 19.1-1%Weak on forward returns (recalculated)
2026-06-21P/E 19.1-1%Weak on forward returns (recalculated)
2026-07-02P/E 21.9+13%Weak on forward returns (recalculated)
2026-07-06P/E 22.1+14%Weak on forward returns (recalculated)
2026-07-09P/E 22.1+14%Weak on forward returns (recalculated)
2026-07-12P/E 21.8+12%Weak on forward returns (recalculated)
2026-07-13P/E 21.8+12%Weak on forward returns (recalculated)
2026-07-14P/E 21.8+12%Weak on forward returns (recalculated)
2026-07-20P/E 21.3+10%Weak on forward returns (recalculated)
2026-07-22P/E 21.3+10%Weak on forward returns (recalculated)
2026-07-25P/E 21.4+10%Weak on forward returns (recalculated)
2026-07-27P/E 21.4+10%Weak on forward returns (recalculated)
2026-07-31P/E 22.0+13%Weak on forward returns (recalculated)
2026-08-03P/E 21.8+12%Weak on forward returns
2026-08-07P/E 21.8+12%Weak on forward returns (recalculated)
2026-08-10P/E 21.9+13%Weak on forward returns
2026-08-14P/E 22.4+16%Weak on forward returns (recalculated)
2026-08-17P/E 22.3+15%Weak on forward returns
2026-08-21P/E 23.7+22%Trading above its usual valuation (recalculated)
2026-08-24P/E 23.8+23%Trading above its usual valuation
2026-08-27P/E 23.8+23%Trading above its usual valuation (recalculated)
2026-08-28P/E 24.7+27%Poor on forward returns (recalculated)
2026-08-30P/E 24.5+26%Poor on forward returns (recalculated)
2026-08-31P/E 24.5+26%Poor on forward returns
2026-09-05P/E 24.8+28%Poor on forward returns (recalculated)
2026-09-07P/E 24.8+28%Poor on forward returns
2026-09-12P/E 23.6+22%Trading above its usual valuation (recalculated)
2026-09-14P/E 23.6+22%Trading above its usual valuation
2026-09-19P/E 27.2+40%Significantly overvalued (recalculated)
2026-09-21P/E 27.2+40%Significantly overvalued
2026-09-26P/E 28.7+48%Significantly overvalued (recalculated)
2026-09-28P/E 28.7+48%Significantly overvalued
2026-10-03P/E 28.7+48%Significantly overvalued (recalculated)
2026-10-05P/E 28.7+48%Significantly overvalued ← now

Frequently asked questions

Is Revvity stock overvalued?

At a blended P/E of 28.7 versus its historical normal P/E of 19.4, Revvity trades about 48% above its typical valuation, with a PEG of 3.05 on 9.4% forward growth. tickerseer currently rates it significantly overvalued.

What is Revvity's fair value and PEG?

Revvity trades at a blended P/E of 28.7 against a historical normal P/E of 19.4, a PEG of 3.05, and a forward growth estimate of 9.4%. Priced at its historical normal P/E of 19.4 on the same blended earnings, the 2026-10-02 close of $151.53 corresponds to about $102 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Revvity changed?

tickerseer's rating moved from weak on forward returns (2026-06-03) to significantly overvalued (2026-10-05).

What is the analyst price target for Revvity?

The mean Wall Street price target for Revvity is $130.27 across 15 analysts, 14.4% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track RVTY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.